News and Trends 24 Oct 2022 New method of observing cell transport could inspire drug development Membrane proteins are key targets for many drugs. Some of them, called transporters, move certain substances in and out of the cellular environment. Yet, extracting and storing them for observation is particularly complex. A team from the University of Geneva (UNIGE) in Switzerland, in collaboration with the University of Zurich (UZH), has developed an innovative […] October 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 24 Oct 2022 Sensorion gets go-ahead from France for trial of drug to prevent hearing loss Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […] October 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 24 Oct 2022 Mass production of lutetium for targeted cancer therapeutics following collaboration An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […] October 24, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Opinion 24 Oct 2022 Hiding in plain sight: how to solve bioscience’s software problem Guy Levy-Yurista, CEO of the experiment platform developer Synthace, gives his take on what’s missing in increasingly software-dependent life sciences labs: a holistic mindset for improving experimental methods. There’s a major problem holding back progress in biotech, and more widely in the life sciences. It’s not an obvious one, but based on the conversations I […] October 24, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2022 Watch: NLS Days NLSInvest award winners – MyoPax The two biotech start-up companies MyoPax and Asgards Therapeutics won first and second prize at NLSINvest Awards, out of 40 companies that participated in Nordic Life Science Days’ start-up pitching challenge. 40 selected Nordic start-up companies attended Nordic Life Science Days, the largest partnering conference for life sciences in the Nordics, in Malmö. As part […] October 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2022Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems This week, we have three guests. We have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidate […] October 21, 2022 Share WhatsApp Twitter Linkedin Email
Inside Labiotech 21 Oct 2022 Meet Bárbara, our new sales representative We’re very excited to welcome Bárbara to our team! She will be working with us to help the biopharma and biotech industries connect and grow. Let’s take a look at why she decided to join us and her ambitions with Labiotech. Bárbara Leite, Sales Representative From Porto, Portugal Bárbara, to start with, how would you […] October 21, 2022 - 3 minutesmins - By Yi-Jen Chang Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Sunshine Biopharma acquires Nora Pharma Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […] October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Spanish research institution to use Elicera Therapeutics’ iTANK platform Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email